Perseus ProteomicsPerseus Proteomics Inc.4882東証グロース医薬品FY ending Mar 2026, non-consolidated, J-GAAP
Perseus Proteomics brought in ¥94.2M in revenue.
It lost about ¥741 for every ¥100 of sales at the operating level.
Revenue changed +31.0% from the prior year.
FY ending Mar 2022 → FY ending Mar 2023
FY ending Mar 2022 → FY ending Mar 2023
For every ¥100 Perseus Proteomics sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
EDINET (FSA Japan)
訂正有価証券報告書-第26期(2025/04/01-2026/03/31)
EDINET (FSA Japan)
有価証券報告書-第25期(2024/04/01-2025/03/31)
EDINET (FSA Japan)
有価証券報告書-第24期(2023/04/01-2024/03/31)
EDINET (FSA Japan)
訂正有価証券報告書-第23期(2022/04/01-2023/03/31)
EDINET (FSA Japan)
有価証券報告書-第22期(令和3年4月1日-令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書-第21期(令和2年4月1日-令和3年3月31日)
Extracted from XBRL: 40 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.